What is SLDB's current stock price?

SLDB (Solid Biosciences Inc.) is currently trading at $6.78 with a market cap of $528.2M.

What sector is Solid Biosciences Inc. in?

Solid Biosciences Inc. (SLDB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SLDB a good stock to buy?

Analysts have a Buy consensus on SLDB with a price target of $16.67. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SLDB Solid Biosciences Inc.

Healthcare

$6.78+0.00%OpenMarket Cap: $528.2M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.94

P/S

0.00

EV/EBITDA

-1.25

DCF Value

$0.41

FCF Yield

-33.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-74.5%

ROA

-45.3%

ROIC

-49.8%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-56.7M	$—
Q4 null	$0.00	$-49.8M	$—
FY null	$0.00	$-174.3M	$—
Q3 null	$0.00	$-45.8M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$16.67

Target (Median)

$16.00

Target Range

$16.00 - $18.00

4 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell

WedbushOutperform

2026-05-18

Piper SandlerOverweight

2026-05-13

JP MorganOverweight

2026-03-25

HC Wainwright & Co.Buy

2026-03-23

Chardan CapitalBuy

2026-03-20

Trading Activity

Insider Trades

View All

Tan Kevinofficer: CFO & Treasurer

SellTue Apr 21

Howton David Tofficer: Chief Operating Officer

SellTue Apr 21

Herzich Paulofficer: Chief Technology Officer

SellTue Apr 21

Hanrahan Jessieofficer: Chief Regulatory Officer

SellTue Apr 21

Cumbo Alexanderdirector, officer: President and CEO

SellTue Apr 21

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

2.47

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Peers

QSI